Evolution of Physical Status From Diagnosis to the End of First-Line Treatment in Breast, Lung, and Colorectal Cancer Patients: The PROTECT-01 Cohort Study Protocol

Joris Mallard, Elyse Hucteau, Roland Schott, Thierry Petit, Martin Demarchi, Christine Belletier, Meher Ben Abdelghani, Hélène Carinato, Pascale Chiappa, Cathie Fischbach, Michal Kalish-Weindling, Audren Bousinière, Stéphane Dufour, Fabrice Favret, Xavier Pivot, Thomas J Hureau, Allan F Pagano, Joris Mallard, Elyse Hucteau, Roland Schott, Thierry Petit, Martin Demarchi, Christine Belletier, Meher Ben Abdelghani, Hélène Carinato, Pascale Chiappa, Cathie Fischbach, Michal Kalish-Weindling, Audren Bousinière, Stéphane Dufour, Fabrice Favret, Xavier Pivot, Thomas J Hureau, Allan F Pagano

Abstract

Background: Cancer cachexia and exacerbated fatigue represent two hallmarks in cancer patients, negatively impacting their exercise tolerance and ultimately their quality of life. However, the characterization of patients' physical status and exercise tolerance and, most importantly, their evolution throughout cancer treatment may represent the first step in efficiently counteracting their development with prescribed and tailored exercise training. In this context, the aim of the PROTECT-01 study will be to investigate the evolution of physical status, from diagnosis to the end of first-line treatment, of patients with one of the three most common cancers (i.e., lung, breast, and colorectal). Methods: The PROTECT-01 cohort study will include 300 patients equally divided between lung, breast and colorectal cancer. Patients will perform a series of assessments at three visits throughout the treatment: (1) between the date of diagnosis and the start of treatment, (2) 8 weeks after the start of treatment, and (3) after the completion of first-line treatment or at the 6-months mark, whichever occurs first. For each of the three visits, subjective and objective fatigue, maximal voluntary force, body composition, cachexia, physical activity level, quality of life, respiratory function, overall physical performance, and exercise tolerance will be assessed. Discussion: The present study is aimed at identifying the nature and severity of maladaptation related to exercise intolerance in the three most common cancers. Therefore, our results should contribute to the delineation of the needs of each group of patients and to the determination of the most valuable exercise interventions in order to counteract these maladaptations. This descriptive and comprehensive approach is a prerequisite in order to elaborate, through future interventional research projects, tailored exercise strategies to counteract specific symptoms that are potentially cancer type-dependent and, in fine, to improve the health and quality of life of cancer patients. Moreover, our concomitant focus on fatigue and cachexia will provide insightful information about two factors that may have substantial interaction but require further investigation. Trial registration: This prospective study has been registered at ClinicalTrials.gov (NCT03956641), May, 2019.

Keywords: cachexia; cachexia-fatigue vicious cycle; cancer-related fatigue; exercise intolerance; muscle wasting; tumor.

Copyright © 2020 Mallard, Hucteau, Schott, Petit, Demarchi, Belletier, Ben Abdelghani, Carinato, Chiappa, Fischbach, Kalish-Weindling, Bousinière, Dufour, Favret, Pivot, Hureau and Pagano.

Figures

Figure 1
Figure 1
Illustration of the theoretical cachexia–fatigue vicious cycle.
Figure 2
Figure 2
Flowchart of the PROTECT-01 study design.
Figure 3
Figure 3
Illustration of the neuromuscular assessments. Participant's position for finger flexor (A) and knee extensor (B) assessments and schematic representation of the protocol (C).

References

    1. Barnes EA, Bruera E. Fatigue in patients with advanced cancer: a review. Int J Gynecol Cancer Off J Int Gynecol Cancer Soc. (2002) 12:424–8. 10.1136/ijgc-00009577-200209000-00002
    1. Ahlberg K, Ekman T, Gaston-Johansson F, Mock V. Assessment and management of cancer-related fatigue in adults. Lancet Lond Engl. (2003) 362:640–50. 10.1016/S0140-6736(03)14186-4
    1. Baracos VE, Martin L, Korc M, Guttridge DC, Fearon KCH. Cancer-associated cachexia. Nat Rev Dis Primer. (2018) 4:17105. 10.1038/nrdp.2017.105
    1. Fearon K, Strasser F, Anker SD, Bosaeus I, Bruera E, Fainsinger RL, et al. . Definition and classification of cancer cachexia: an international consensus. Lancet Oncol. (2011) 12:489–95. 10.1016/S1470-2045(10)70218-7
    1. Neefjes ECW, van den Hurk RM, Blauwhoff-Buskermolen S, van der Vorst MJDL, Becker-Commissaris A, de van der Schueren MAE, et al. . Muscle mass as a target to reduce fatigue in patients with advanced cancer. J Cachexia Sarcopenia Muscle. (2017) 8:623–9. 10.1002/jcsm.12199
    1. Bye A, Sjøblom B, Wentzel-Larsen T, Grønberg BH, Baracos VE, Hjermstad MJ, et al. . Muscle mass and association to quality of life in non-small cell lung cancer patients. J Cachexia Sarcopenia Muscle. (2017) 8:759–67. 10.1002/jcsm.12206
    1. Prigerson HG, Bao Y, Shah MA, Paulk ME, LeBlanc TW, Schneider BJ, et al. . Chemotherapy use, performance status, and quality of life at the end of life. JAMA Oncol. (2015) 1:778–84. 10.1001/jamaoncol.2015.2378
    1. Jones JM, Olson K, Catton P, Catton CN, Fleshner NE, Krzyzanowska MK, et al. . Cancer-related fatigue and associated disability in post-treatment cancer survivors. J Cancer Surviv Res Pract. (2016) 10:51–61. 10.1007/s11764-015-0450-2
    1. Pressoir M, Desné S, Berchery D, Rossignol G, Poiree B, Meslier M, et al. . Prevalence, risk factors and clinical implications of malnutrition in French comprehensive cancer centres. Br J Cancer. (2010) 102:966–71. 10.1038/sj.bjc.6605578
    1. Dudgeon DJ, Kristjanson L, Sloan JA, Lertzman M, Clement K. Dyspnea in cancer patients: prevalence and associated factors. J Pain Symptom Manage. (2001) 21:95–102. 10.1016/S0885-3924(00)00258-X
    1. Quinten C, Martinelli F, Coens C, Sprangers MAG, Ringash J, Gotay C, et al. . A global analysis of multitrial data investigating quality of life and symptoms as prognostic factors for survival in different tumor sites. Cancer. (2014) 120:302–11. 10.1002/cncr.28382
    1. Raoof A, Yacoub S, Asaad Y, Hadithi TA. Quality of life among cancer patients treated with chemotherapy or radiotherapy in erbil city an evaluation study. Cancer Clin Oncol. (2015) 4:19 10.5539/cco.v4n1p19
    1. Enoka RM, Duchateau J. Translating fatigue to human performance. Med Sci Sports Exerc. (2016) 48:2228–38. 10.1249/MSS.0000000000000929
    1. Wagner LI, Cella D. Fatigue and cancer: causes, prevalence and treatment approaches. Br J Cancer. (2004) 91:822–28. 10.1038/sj.bjc.6602012
    1. Cella D, Davis K, Breitbart W, Curt G, Fatigue Coalition. Cancer-related fatigue: prevalence of proposed diagnostic criteria in a United States sample of cancer survivors. J Clin Oncol. (2001) 19:3385–91. 10.1200/JCO.2001.19.14.3385
    1. Curt GA, Breitbart W, Cella D, Groopman JE, Horning SJ, Itri LM, et al. . Impact of cancer-related fatigue on the lives of patients: new findings from the fatigue coalition. Oncologist. (2000) 5:353–60. 10.1634/theoncologist.5-5-353
    1. Ferriolli E, Skipworth RJE, Hendry P, Scott A, Stensteth J, Dahele M, et al. Physical activity monitoring: a responsive and meaningful patient-centered outcome for surgery, chemotherapy, or radiotherapy? J Pain Symptom Manage. (2012) 43:1025–35. 10.1016/j.jpainsymman.2011.06.013
    1. Christensen JF, Jones LW, Andersen JL, Daugaard G, Rorth M, Hojman P. Muscle dysfunction in cancer patients. Ann Oncol. (2014) 25:947–58. 10.1093/annonc/mdt551
    1. Brioche T, Pagano AF, Py G, Chopard A. Muscle wasting and aging: experimental models, fatty infiltrations, and prevention. Mol Aspects Med. (2016) 50:56–87. 10.1016/j.mam.2016.04.006
    1. Bodine SC. Disuse-induced muscle wasting. Int J Biochem Cell Biol. (2013) 45:2200–8. 10.1016/j.biocel.2013.06.011
    1. Chopard A, Hillock S, Jasmin BJ. Molecular events and signalling pathways involved in skeletal muscle disuse-induced atrophy and the impact of countermeasures. J Cell Mol Med. (2009) 13:3032–50. 10.1111/j.1582-4934.2009.00864.x
    1. Demangel R, Treffel L, Py G, Brioche T, Pagano AF, Bareille M-P, et al. . Early structural and functional signature of 3-day human skeletal muscle disuse using the dry immersion model. J Physiol. (2017) 595:4301–15. 10.1113/JP273895
    1. Oikawa SY, Holloway TM, Phillips SM. The impact of step reduction on muscle health in aging: protein and exercise as countermeasures. Front Nutr. (2019) 6:75. 10.3389/fnut.2019.00075
    1. Evans WJ, Morley JE, Argilés J, Bales C, Baracos V, Guttridge D, et al. . Cachexia: a new definition. Clin Nutr Edinb Scotl. (2008) 27:793–99. 10.1016/j.clnu.2008.06.013
    1. Madeddu C, Mantovani G, Gramignano G, Astara G, Macciò A. Muscle wasting as main evidence of energy impairment in cancer cachexia: future therapeutic approaches. Future Oncol Lond Engl. (2015) 11:2697–710. 10.2217/fon.15.195
    1. Macciò A, Busquets S, Madeddu C, Argilés JM. Editorial: biological mechanism-based and patient-centered management of cancer-related symptoms and syndromes. Front Physiol. (2018) 9:1819. 10.3389/fphys.2018.01819
    1. Farkas J, von Haehling S, Kalantar-Zadeh K, Morley JE, Anker SD, Lainscak M. Cachexia as a major public health problem: frequent, costly, and deadly. J Cachexia Sarcopenia Muscle. (2013) 4:173–8. 10.1007/s13539-013-0105-y
    1. Martin L, Senesse P, Gioulbasanis I, Antoun S, Bozzetti F, Deans C, et al. . Diagnostic criteria for the classification of cancer-associated weight loss. J Clin Oncol. (2015) 33:90–9. 10.1200/JCO.2014.56.1894
    1. Arthur ST, Noone JM, Van Doren BA, Roy D, Blanchette CM. One-year prevalence, comorbidities and cost of cachexia-related inpatient admissions in the USA. Drugs Context. (2014) 3:212265. 10.7573/dic.212265
    1. Ryan JL, Carroll JK, Ryan EP, Mustian KM, Fiscella K, Morrow GR. Mechanisms of cancer-related fatigue. Oncologist. (2007) 12:22–34. 10.1634/theoncologist.12-S1-22
    1. Powers SK, Lynch GS, Murphy KT, Reid MB, Zijdewind I. Disease-induced skeletal muscle atrophy and fatigue. Med Sci Sports Exerc. (2016) 48:2307–19. 10.1249/MSS.0000000000000975
    1. Roberts BM, Frye GS, Ahn B, Ferreira LF, Judge AR. Cancer cachexia decreases specific force and accelerates fatigue in limb muscle. Biochem Biophys Res Commun. (2013) 435:488–92. 10.1016/j.bbrc.2013.05.018
    1. Kelley GA, Kelley KS. Exercise and cancer-related fatigue in adults: a systematic review of previous systematic reviews with meta-analyses. BMC Cancer. (2017) 17:693. 10.1186/s12885-017-3687-5
    1. Mustian KM, Peppone L, Darling TV, Palesh O, Heckler CE, Morrow GR. A 4-week home-based aerobic and resistance exercise program during radiation therapy: a pilot randomized clinical trial. J Support Oncol. (2009) 7:158–167.
    1. Cramp F, Daniel J. Exercise for the management of cancer-related fatigue in adults. Cochrane Database Syst Rev. (2008) 11:CD006145. 10.1002/14651858.CD006145.pub2
    1. Bowen TS, Schuler G, Adams V. Skeletal muscle wasting in cachexia and sarcopenia: molecular pathophysiology and impact of exercise training. J Cachexia Sarcopenia Muscle. (2015) 6:197–207. 10.1002/jcsm.12043
    1. Gould DW, Lahart I, Carmichael AR, Koutedakis Y, Metsios GS. Cancer cachexia prevention via physical exercise: molecular mechanisms. J Cachexia Sarcopenia Muscle. (2013) 4:111–24. 10.1007/s13539-012-0096-0
    1. Hardee JP, Counts BR, Carson JA. Understanding the role of exercise in cancer cachexia therapy. Am J Lifestyle Med. (2019) 13:46–60. 10.1177/1559827617725283
    1. INCa Plan Cancer 2014–2019 (2015).
    1. INSERM Activité Physique: Prévention et Traitement des Maladies Chroniques. Collection Expertise collective. Montrouge: EDP Sciences; (2019).
    1. Hayes SC, Newton RU, Spence RR, Galvão DA. The exercise and sports science Australia position statement: exercise medicine in cancer management. J Sci Med Sport. (2019) 22:1175–99. 10.1016/j.jsams.2019.05.003
    1. Schmitz KH, Courneya KS, Matthews C, Demark-Wahnefried W, Galvão DA, Pinto BM, et al. . American college of sports medicine roundtable on exercise guidelines for cancer survivors. Med Sci Sports Exerc. (2010) 42:1409–26. 10.1249/MSS.0b013e3181e0c112
    1. Stefani L, Galanti G, Klika R. Clinical implementation of exercise guidelines for cancer patients: adaptation of ACSM's guidelines to the Italian model. J Funct Morphol Kinesiol. (2017) 2:4 10.3390/jfmk2010004
    1. Stout NL, Baima J, Swisher AK, Winters-Stone KM, Welsh J. A systematic review of exercise systematic reviews in the cancer literature (2005-2017). PM R. (2017) 9:S347–84. 10.1016/j.pmrj.2017.07.074
    1. Buffart LM, Kalter J, Sweegers MG, Courneya KS, Newton RU, Aaronson NK, et al. . Effects and moderators of exercise on quality of life and physical function in patients with cancer: an individual patient data meta-analysis of 34 RCTs. Cancer Treat Rev. (2017) 52:91–104. 10.1016/j.ctrv.2016.11.010
    1. Jones LW, Eves ND, Haykowsky M, Freedland SJ, Mackey JR. Exercise intolerance in cancer and the role of exercise therapy to reverse dysfunction. Lancet Oncol. (2009) 10:598–605. 10.1016/S1470-2045(09)70031-2
    1. Brown JC, Huedo-Medina TB, Pescatello LS, Pescatello SM, Ferrer RA, Johnson BT. Efficacy of exercise interventions in modulating cancer-related fatigue among adult cancer survivors: a meta-analysis. Cancer Epidemiol Biomark Prev. (2011) 20:123–33. 10.1158/1055-9965.EPI-10-0988
    1. Cormie P, Zopf EM, Zhang X, Schmitz KH. The impact of exercise on cancer mortality, recurrence, and treatment-related adverse effects. Epidemiol Rev. (2017) 39:71–92. 10.1093/epirev/mxx007
    1. van der Leeden M, Huijsmans RJ, Geleijn E, de Rooij M, Konings IR, Buffart LM, et al. . Tailoring exercise interventions to comorbidities and treatment-induced adverse effects in patients with early stage breast cancer undergoing chemotherapy: a framework to support clinical decisions. Disabil Rehabil. (2018) 40:486–96. 10.1080/09638288.2016.1260647
    1. Abdel-Qadir H, Thavendiranathan P, Austin PC, Lee DS, Amir E, Tu JV, et al. . The risk of heart failure and other cardiovascular hospitalizations after early stage breast cancer: a matched cohort study. J Natl Cancer Inst. (2019) 111:854–62. 10.1093/jnci/djy218
    1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. (2018) 68:394–424. 10.3322/caac.21492
    1. Butt Z, Lai J, Rao D, Heinemann AW, Bill A, Cella D. Measurement of fatigue in cancer, stroke, and HIV using the functional assessment of chronic illness therapy–fatigue (FACIT-F) scale. J Psychosom Res. (2013) 74:64–8. 10.1016/j.jpsychores.2012.10.011
    1. Armstrong T, Bull F. Development of the World Health Organization Global Physical Activity Questionnaire (GPAQ). J Public Health. (2006) 14:66–70. 10.1007/s10389-006-0024-x
    1. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. . The european organization for research and treatment of cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. (1993) 85:365–76. 10.1093/jnci/85.5.365
    1. Bosy-Westphal A, Schautz B, Later W, Kehayias JJ, Gallagher D, Müller MJ. What makes a BIA equation unique? Validity of eight-electrode multifrequency BIA to estimate body composition in a healthy adult population. Eur J Clin Nutr. (2013) 67:S14–21. 10.1038/ejcn.2012.160
    1. Benavides-Rodríguez L, García-Hermoso A, Rodrigues-Bezerra D, Izquierdo M, Correa-Bautista JE, Ramírez-Vélez R. Relationship between handgrip strength and muscle mass in female survivors of breast cancer: a mediation analysis. Nutrients. (2017) 9:695. 10.3390/nu9070695
    1. Freitag N, Weber PD, Sanders TC, Schulz H, Bloch W, Schumann M. High-intensity interval training and hyperoxia during chemotherapy. Medicine (Baltimore). (2018) 97:e11068. 10.1097/MD.0000000000011068
    1. Lundberg M, Dickinson A, Nikander P, Orell H, Mäkitie A. Low-phase angle in body composition measurements correlates with prolonged hospital stay in head and neck cancer patients. Acta Otolaryngol (Stockh). (2019) 139:383–7. 10.1080/00016489.2019.1566779
    1. Ferrario C, Cosentino D, Lines H, Cross T, Dixon S. Factors influencing the length of stay for breast cancer patients undergoing mastectomy: an independent sector perspective. Eur J Surg Oncol. (2016) 42:S23 10.1016/j.ejso.2016.02.094
    1. Mathiowetz V. Grip and pinch strength measurements. In: Amundsen LR. ed. Muscle Strength Testing: Instrumented and Non-Instrumented Systems. New York, NY: Churchill Livingstone; (1990). p. 163–7.
    1. Fess EE. Grip strength. In: American Society of Hand Therapists ed. Clinical Assessment Recommendations. 2nd ed Garner, NC: American Society of Hand Therapists; (1992). p. 41–5.
    1. Gandevia SC. Spinal and supraspinal factors in human muscle fatigue. Physiol Rev. (2001) 81:1725–89. 10.1152/physrev.2001.81.4.1725
    1. Freire AN, Guerra RO, Alvarado B, Guralnik JM, Zunzunegui MV. Validity and reliability of the short physical performance battery in two diverse older adult populations in Quebec and Brazil. J Aging Health. (2012) 24:863–78. 10.1177/0898264312438551
    1. Guralnik JM, Ferrucci L, Pieper CF, Leveille SG, Markides KS, Ostir GV, et al. . Lower extremity function and subsequent disability: consistency across studies, predictive models, and value of gait speed alone compared with the short physical performance battery. J Gerontol A Biol Sci Med Sci. (2000) 55:M221–31. 10.1093/gerona/55.4.M221
    1. ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med. (2002) 166:111–7. 10.1164/ajrccm.166.1.at1102
    1. Jones LW, Hornsby WE, Goetzinger A, Forbes LM, Sherrard EL, Quist M, et al. . Prognostic significance of functional capacity and exercise behavior in patients with metastatic non-small cell lung cancer. Lung Cancer. (2012) 76:248–52. 10.1016/j.lungcan.2011.10.009
    1. Demers C, McKelvie RS, Negassa A, Yusuf S, RESOLVD Pilot Study Investigators . Reliability, validity, and responsiveness of the six-minute walk test in patients with heart failure. Am Heart J. (2001) 142:698–703. 10.1067/mhj.2001.118468
    1. Charan J, Biswas T. How to calculate sample size for different study designs in medical research? Indian J Psychol Med. (2013) 35:121–6. 10.4103/0253-7176.116232
    1. Granger CL, Holland AE, Gordon IR, Denehy L. Minimal important difference of the 6-minute walk distance in lung cancer. Chron Respir Dis. (2015) 12:146–54. 10.1177/1479972315575715
    1. Camarri B, Eastwood PR, Cecins NM, Thompson PJ, Jenkins S. Six minute walk distance in healthy subjects aged 55-75 years. Respir Med. (2006) 100:658–65. 10.1016/j.rmed.2005.08.003
    1. Veni T, Boyas S, Beaune B, Bourgeois H, Rahmani A, Landry S, et al. . Handgrip fatiguing exercise can provide objective assessment of cancer-related fatigue: a pilot study. Support Care Cancer. (2019) 27:229–38. 10.1007/s00520-018-4320-0
    1. Kilgour RD, Vigano A, Trutschnigg B, Hornby L, Lucar E, Bacon SL, et al. . Cancer-related fatigue: the impact of skeletal muscle mass and strength in patients with advanced cancer. J Cachexia Sarcopenia Muscle. (2010) 1:177–85. 10.1007/s13539-010-0016-0
    1. Twomey R, Martin T, Temesi J, Culos-Reed SN, Millet GY. Tailored exercise interventions to reduce fatigue in cancer survivors: study protocol of a randomized controlled trial. BMC Cancer. (2018) 18:757. 10.1186/s12885-018-4668-z
    1. Abrahams HJ, Gielissen MF, Schmits IC, Verhagen CA, Rovers MM, Knoop H. Risk factors, prevalence, and course of severe fatigue after breast cancer treatment: a meta-analysis involving 12 327 breast cancer survivors. Ann Oncol. (2016) 27:965–74. 10.1093/annonc/mdw099
    1. Zick SM, Sen A, Wyatt GK, Murphy SL, Arnedt JT, Harris RE. Investigation of 2 types of self-administered acupressure for persistent cancer-related fatigue in breast cancer survivors: a randomized clinical trial. JAMA Oncol. (2016) 2:1470–6. 10.1001/jamaoncol.2016.1867
    1. Molassiotis A, Bardy J, Finnegan-John J, Mackereth P, Ryder DW, Filshie J, et al. . Acupuncture for cancer-related fatigue in patients with breast cancer: a pragmatic randomized controlled trial. J Clin Oncol Off J Am Soc Clin Oncol. (2012) 30:4470–6. 10.1200/JCO.2012.41.6222
    1. Mustian KM, Alfano CM, Heckler C, Kleckner AS, Kleckner IR, Leach CR, et al. . Comparison of pharmaceutical, psychological, and exercise treatments for cancer-related fatigue: a meta-analysis. JAMA Oncol. (2017) 3:961–8. 10.1001/jamaoncol.2016.6914
    1. Storey DJ, McLaren DB, Atkinson MA, Butcher I, Frew LC, Smyth JF, et al. . Clinically relevant fatigue in men with hormone-sensitive prostate cancer on long-term androgen deprivation therapy. Ann Oncol. (2012) 23:1542–9. 10.1093/annonc/mdr447
    1. Steens A, Heersema DJ, Maurits NM, Renken RJ, Zijdewind I. Mechanisms underlying muscle fatigue differ between multiple sclerosis patients and controls: a combined electrophysiological and neuroimaging study. NeuroImage. (2012) 59:3110–8. 10.1016/j.neuroimage.2011.11.038
    1. Harridge SD, Magnusson G, Gordon A. Skeletal muscle contractile characteristics and fatigue resistance in patients with chronic heart failure. Eur Heart J. (1996) 17:896–901. 10.1093/oxfordjournals.eurheartj.a014971
    1. Stewart GD, Skipworth RJE, Fearon KCH. Cancer cachexia and fatigue. Clin Med Lond Engl. (2006) 6:140–3. 10.7861/clinmedicine.6-2-140
    1. Lobelo F, Stoutenberg M, Hutber A. The exercise is medicine global health initiative: a 2014 update. Br J Sports Med. (2014) 48:1627–33. 10.1136/bjsports-2013-093080
    1. Lucía A, Earnest C, Pérez M. Cancer-related fatigue: can exercise physiology assist oncologists? Lancet Oncol. (2003) 4:616–25. 10.1016/S1470-2045(03)01221-X
    1. Stene GB, Helbostad JL, Balstad TR, Riphagen II, Kaasa S, Oldervoll LM. Effect of physical exercise on muscle mass and strength in cancer patients during treatment—a systematic review. Crit Rev Oncol Hematol. (2013) 88:573–93. 10.1016/j.critrevonc.2013.07.001
    1. Partridge AH, Burstein HJ, Winer EP. Side effects of chemotherapy and combined chemohormonal therapy in women with early-stage breast cancer. J Natl Cancer Inst Monogr. (2001) 30:135–42. 10.1093/oxfordjournals.jncimonographs.a003451
    1. Mustian KM, Sprod LK, Palesh OG, Peppone LJ, Janelsins MC, Mohile SG, et al. Exercise for the management of side effects and quality of life among cancer survivors. Curr Sports Med Rep. (2009) 8:325–30. 10.1249/JSR.0b013e3181c22324

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir